Novozymes A/S (OTCMKTS:NVZMY) Shares Gap Down - Here's What Happened

Key Points

• Shares of Novozymes A/S gapped down prior to trading, opening at $62.56 after closing at $64.71.
• Zacks Research downgraded Novozymes from a "strong-buy" to a "hold" rating, contributing to a consensus rating of "Moderate Buy".
• The company boasts a market capitalization of $30.14 billion and a P/E ratio of 40.73, indicating strong demand in its sector.

Shares of Novozymes A/S (OTCMKTS:NVZMY - Get Free Report) gapped down prior to trading on Friday . The stock had previously closed at $64.71, but opened at $62.56. Novozymes A/S shares last traded at $63.34, with a volume of 132 shares changing hands.

Analyst Ratings Changes

Separately, Zacks Research lowered shares of Novozymes A/S from a "strong-buy" rating to a "hold" rating in a report on Monday. Two analysts have rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy".

Novozymes A/S Stock Performance

The company has a quick ratio of 1.04, a current ratio of 1.66 and a debt-to-equity ratio of 0.11. The firm has a market capitalization of $30.14 billion, a P/E ratio of 40.73, a price-to-earnings-growth ratio of 1.24 and a beta of 0.90. The company's 50 day moving average is $68.24 and its 200-day moving average is $65.10.

About Novozymes A/S

Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company offers protein solutions for the food and beverage industry. It also offers industrial hygiene, drain openers, hard surface, medical cleaning, septic tanks, ware washing, and professional laundry services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.